2-(1-(benzo[d]thiazol-2-ylmethyl)-4-hydroxy-2-oxo-2,5,7,8-tetrahydro-1H-pyrano[4,3-b]pyridine-3-carboxamido)acetic acid

ID: ALA4162309

Chembl Id: CHEMBL4162309

PubChem CID: 118978341

Max Phase: Preclinical

Molecular Formula: C19H17N3O6S

Molecular Weight: 415.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)CNC(=O)c1c(O)c2c(n(Cc3nc4ccccc4s3)c1=O)CCOC2

Standard InChI:  InChI=1S/C19H17N3O6S/c23-15(24)7-20-18(26)16-17(25)10-9-28-6-5-12(10)22(19(16)27)8-14-21-11-3-1-2-4-13(11)29-14/h1-4,25H,5-9H2,(H,20,26)(H,23,24)

Standard InChI Key:  UWKUIXNEIFYFGM-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4162309

    ---

Associated Targets(Human)

EGLN1 Tclin Egl nine homolog 1 (1702 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGLN3 Tclin Egl nine homolog 3 (250 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGLN2 Tclin Hypoxia-inducible factor prolyl hydroxylase 1 (404 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 415.43Molecular Weight (Monoisotopic): 415.0838AlogP: 1.10#Rotatable Bonds: 5
Polar Surface Area: 130.75Molecular Species: ACIDHBA: 8HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 3.75CX Basic pKa: 2.50CX LogP: -0.64CX LogD: -3.71
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.57Np Likeness Score: -1.21

References

1. Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR..  (2018)  Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.,  61  (16): [PMID:29712435] [10.1021/acs.jmedchem.7b01686]
2. Liu P, Wang L, DuBois BG, Colandrea VJ, Liu R, Cai J, Du X, Quan W, Morris W, Bai J, Bishwokarma B, Cheng M, Piesvaux J, Ray K, Alpert C, Chiu CS, Zielstorff M, Metzger JM, Yang L, Leung D, Alleyne C, Vincent SH, Pucci V, Li X, Crespo A, Stickens D, Hale JJ, Ujjainwalla F, Sinz CJ..  (2018)  Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.,  (12): [PMID:30613325] [10.1021/acsmedchemlett.8b00274]

Source